Respiratory syncytial virus: promising progress against a leading cause of pneumonia

Lancet Glob Health. 2021 Dec;9(12):e1644-e1645. doi: 10.1016/S2214-109X(21)00455-1. Epub 2021 Nov 11.

Authors

Amy Sarah Ginsburg¹, Padmini Srikantiah²

Affiliations

¹ University of Washington Clinical Trials Center, University of Washington, Seattle, WA 98115, USA. Electronic address: [email protected].
² The Bill & Melinda Gates Foundation, Seattle, WA, USA.

No abstract available

MeSH terms

Antiviral Agents / therapeutic use
Humans
Pneumonia / prevention & control*
Respiratory Syncytial Virus Infections / prevention & control*
Respiratory Syncytial Virus Vaccines / immunology
Respiratory Syncytial Virus, Human*

Substances

Antiviral Agents
Respiratory Syncytial Virus Vaccines

Associated data

ClinicalTrials.gov/NCT04424316
ClinicalTrials.gov/NCT04605159
ClinicalTrials.gov/NCT03979313
ClinicalTrials.gov/NCT04767373